REVIEW

The osteocyte: key player in regulating bone turnover

Steven R Goldring

To cite: Goldring SR. The osteocyte: key player in regulating bone turnover. *RMD Open* 2015;1:e000049. doi:10.1136/rmdopen-2015-000049

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/rmdopen-2015-000049>).

Received 2 February 2015
Revised 20 February 2015
Accepted 25 February 2015

ABSTRACT

Osteocytes are the most abundant cell type in bone and are distributed throughout the mineralised bone matrix forming an interconnected network that ideally positions them to sense and to respond to local biomechanical and systemic stimuli to regulate bone remodelling and adaptation. The adaptive process is dependent on the coordinated activity of osteoclasts and osteoblasts that form a so called bone multicellular unit that remodels cortical and trabecular bone through a process of osteoclast-mediated bone resorption, followed by a phase of bone formation mediated by osteoblasts. Osteocytes mediate their effects on bone remodelling via both cell–cell interactions with osteoclasts and osteoblasts, but also via signaling through the release of soluble mediators. The remodelling process provides a mechanism for adapting the skeleton to local biomechanical factors and systemic hormonal influences and for replacing bone that has undergone damage from repetitive mechanical loading.

Throughout postnatal life bone undergoes continuous structural reorganisation and adaptation. The adaptive process is dependent on the coordinated activity of osteoclasts and osteoblasts that form a so called bone multicellular unit (BMU) that remodels cortical and trabecular bone through a process of osteoclast-mediated bone resorption, followed by a phase of bone formation mediated by osteoblasts.¹ The remodelling process provides a mechanism for adapting the skeleton to local biomechanical factors and systemic hormonal influences and for replacing bone that has undergone damage from repetitive mechanical loading.^{2 3}

Importantly, under physiological conditions, the amount of bone that is removed during the phase of bone resorption is matched by the amount of bone that is added by bone formation. The mechanisms involved in ‘coupling’ of bone resorption and formation are mediated in part by the release of bone growth factors, including transforming

growth factor- β (TGF- β) and bone morphogenetic proteins (BMPs), which are released from the bone matrix during the phase of bone resorption.^{4 5} Osteoclasts provide an additional source of coupling factors including BMP-6, sphingosine-1-phosphate and Wnt-10b that induce osteoblast-mediated bone formation.^{6 7} Osteoclasts also produce factors that inhibit osteoblast differentiation and activity.⁸

Although there have been major advances in identifying the mechanisms involved in the regulation of osteoclast and osteoblast differentiation and activity, the specific cellular events associated with activation of BMUs and the initiation of bone remodelling until recently have been a matter of controversy. Rodan and Martin⁹ first proposed a key role of osteoblasts in initiating bone remodelling through the release of pro-osteoclastogenic mediators. Recent studies using a variety of experimental approaches have, however, challenged this concept. For example, Corral *et al*¹⁰ and more recently Galli *et al*¹¹ used genetic approaches to delete mature osteoblasts in mouse models and showed that this did not affect osteoclast-mediated bone resorption. Importantly, morphological studies demonstrate that mature bone forming osteoblasts are not present during the activation of the BMU,¹ indicating that alternate mechanisms must be involved in the initiation of bone remodelling.

Several lines of evidence have now established a key for osteocytes in the regulation of bone remodelling.^{12 13} Osteocytes are the most abundant cell type in bone and are distributed throughout the mineralised bone matrix forming an interconnected network that ideally positions them to sense and to respond to local and systemic stimuli to regulate bone remodelling and adaptation. These effects are mediated via both cell–cell interactions with osteoclasts and osteoblasts but also via signalling through the release of soluble mediators. Recent studies by Xiong

CrossMark

Research Division, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York, USA

Correspondence to
Dr Steven R Goldring;
goldrings@hss.edu

*et al*¹⁴ and Nakashima *et al*¹⁵ provide convincing evidence supporting a critical role for osteocytes in regulating the effects of mechanical loading on bone remodelling. They deleted receptor activator of NF- κ B ligand (RANKL), the master regulator of osteoclastogenesis, in osteocytes and showed that the animals developed an osteopetrotic phenotype and were resistant to bone loss induced by mechanical unloading using tail vein suspension. These findings support the observations of Tatsumi *et al*¹⁶ who used genetic approaches to selectively ablate osteocytes and showed that the animals lost the capacity to increase bone loss in response to unloading. Osteocytes also are a source of osteoprotegerin (OPG), the potent inhibitor of RANKL,¹⁷ and differential production of OPG and RANKL by osteocytes provides a unique mechanism by which osteocytes can regulate osteoclast-mediated bone resorption (figure 1).

In addition to OPG and RANKL, osteocytes are the source of a diverse array of products that have the capacity to modulate bone remodelling, including small molecule mediators such as prostanoids, nitric oxide, and nucleotides, as well as a broad spectrum of cytokines and growth factors such as insulin-like growth factor-1 (IGF-1), vascular endothelial cell growth factor (VEGF) and TGF- β .^{13 18–24} Osteocytes also are a major source of fibroblast growth factor 23, which regulates serum phosphorus levels by increasing renal phosphate excretion.²⁵ Recent studies have drawn attention to the role of two osteocyte-derived products, sclerostin and Dickkopf-related protein 1 (DKK-1), in the regulation of bone remodelling. These molecules are potent and specific inhibitors of the Wnt/ β -catenin pathway, which plays a major role in the regulation of osteoblast-mediated bone formation.²⁶ Robling and co-workers were the first to show that mechanical loading decreased the expression of sclerostin and DKK-1 in osteocytes. The decrease in the production of these Wnt pathway inhibitors by osteocytes resulted in upregulation of β -catenin signaling in osteoblasts and an associated

Figure 1 Osteocyte-derived receptor activator of NF- κ B ligand (RANKL) increases bone resorption. Osteocytes control unloading-induced bone loss by induction of RANKL in osteocytes, which results in increased osteoclast-mediated bone resorption.

Figure 2 Osteocyte-derived sclerostin and Dickkopf-related protein 1 (DKK-1) regulate bone formation. Loading decreases osteocyte-derived sclerostin and DKK-1, which results in activation of the Wnt/ β -catenin signaling in osteoblasts and increased bone formation.

increase in bone formation^{27–29} (figure 2). In contrast, unloading resulted in increased expression of sclerostin and DKK-1 and reduction in bone formation. Osteocytes also play a role in mediating the effects of parathyroid hormone (PTH) on bone formation. These effects are in part attributable to PTH-induced suppression of sclerostin by osteocytes.^{30–32} In addition, there is evidence that PTH-induces increases in RANKL production by osteocytes, indicating a key role of osteocytes in mediating the effects of PTH on osteoclast-mediated bone resorption.³³

Studies by Morse *et al*³⁴ have provided further insights into the role of osteocyte-derived sclerostin in regulation of bone formation. They examined the effects of loading and unloading in mice in which the *Sost* gene was deleted in osteocytes. Sclerostin is the product of the *Sost* gene and deletion of *Sost* resulted in loss of sclerostin production by osteocytes. They found that mice lacking the gene maintained the capacity to increase bone mass in response to loading, indicating the existence of sclerostin-independent mechanisms for regulating bone formation. In contrast, bone loss was attenuated in the mice that lacked the *Sost* gene, indicating that osteocyte-derived sclerostin played a key role in mediating the effects of unloading on bone formation. The loss of bone was attributable to a decrease in bone formation but also an effect on bone resorption, indicating that in addition to effects on bone formation, sclerostin and the Wnt/ β -catenin pathway in osteocytes also contributes to the regulation of osteoclast-mediated bone resorption. This effects is in part related to a decrease in osteocyte-derived OPG resulting in a shift in the RANKL/OPG ratio favouring increased RANKL-mediated osteoclastogenesis.

As discussed above, in addition to the role of bone remodelling in providing a mechanism for adapting the skeleton to mechanical loading and systemic hormones, BMU-mediated bone remodelling also provides a mechanism for replacing bone that has undergone damage

from repetitive mechanical loading. The term ‘targeted remodelling’ has been used to identify the process of remodelling of bone that has undergone microdamage.^{2,3} Studies by Schaffler *et al* have provided insights into the mechanisms of targeted remodelling.^{13,21,35,36} They showed that the remodelling process at sites of microdamage is initiated by apoptosis of osteocytes at the sites of bone damage, and that osteocytes adjacent to the dying cells release products, including RANKL, VEGF, ATP, sphingosine-1-phosphate and chemokines that activate endothelial cells and recruit bone cell precursors, including osteoclasts and osteoblasts, to the site of injury where they can repair the damage through BMU-mediated remodelling. Targeted remodelling of subchondral bone at sites of excessive mechanical loading play a contributory role in the adaptive bone changes in osteoarthritis (OA).

Several recent reports have provided insights into the potential contributory role of osteocyte-derived sclerostin and the Wnt/ β -catenin pathway in the development of OA bone pathology.^{37–40} For example, Chan *et al*³⁸ examined the expression of sclerostin in osteochondral samples from human subjects with OA and sheep and mice with surgically induced OA. They found decreased expression of sclerostin in osteocytes in regions corresponding to sites of increased mechanical loading and associated increased bone formation. Appel *et al*³⁷ also observed evidence of decreased sclerostin expression in regions of subchondral bone pathology in samples from patients with OA. In other studies Funck-Brentano *et al*³⁹ used the TOPGAL reporter mice to assess activation of Wnt/ β -catenin signaling in joint tissues. This system permits detection of the specific cellular localisation of activation of the Wnt/ β -catenin signaling pathway using X-gal staining of the tissue sections. They found that X-gal staining was increased in osteocytes in subchondral bone at sites of increased subchondral bone formation. They also showed increased VEGF in osteoblasts and osteocytes in the subchondral bone in meniscectomised mice with OA.

In summary, recent studies have identified osteocytes as the key regulators of bone remodelling in both physiological as well as pathological states. Osteocytes are widely distributed throughout the bone matrix and are optimally positioned to sense and respond to changes in mechanical loading and to local bone damage. They also have the capacity to regulate bone remodelling in response to systemic hormones. Osteocytes exert their effects on bone remodelling via direct cell–cell contacts and by the release of soluble mediators that control the recruitment, differentiation and activity of osteoclasts and osteoblasts. Targeting osteocytes and their products represents a novel approach to treating skeletal disorders associated with de-regulated bone remodelling.

Competing interests None declared.

Provenance and peer review Commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Eriksen EF. Cellular mechanisms of bone remodeling. *Rev Endocr Metab Disord* 2010;11:219–27.
2. Cardoso L, Herman BC, Verborgt O, *et al*. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. *J Bone Miner Res* 2009;24:597–605.
3. Martin RB. Targeted bone remodeling involves BMU steering as well as activation. *Bone* 2007;40:1574–80.
4. Nistala H, Lee-Arteaga S, Siciliano G, *et al*. Extracellular regulation of transforming growth factor beta and bone morphogenetic protein signaling in bone. *Ann N Y Acad Sci* 2010;1192:253–6.
5. Wu X, Shi W, Cao X. Multiplicity of BMP signaling in skeletal development. *Ann N Y Acad Sci* 2007;1116:29–49.
6. Purdue PE, Crotti TN, Shen Z, *et al*. Comprehensive profiling analysis of actively resorbing osteoclasts identifies critical signaling pathways regulated by bone substrate. *Sci Rep* 2014;4:7595.
7. Pederson L, Ruan M, Westendorf JJ, *et al*. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. *Proc Natl Acad Sci USA* 2008;105:20764–9.
8. Negishi-Koga T, Shinohara M, Komatsu N, *et al*. Suppression of bone formation by osteoclastic expression of semaphorin 4D. *Nat Med* 2011;17:1473–80.
9. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption—a hypothesis. *Calcif Tissue Int* 1982;34:311.
10. Corral DA, Amling M, Priemel M, *et al*. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. *Proc Natl Acad Sci U S A* 1998;95:13835–40.
11. Galli C, Fu Q, Wang W, *et al*. Commitment to the osteoblast lineage is not required for RANKL gene expression. *J Biol Chem* 2009;284:12654–62.
12. Bonewald LF. The amazing osteocyte. *J Bone Miner Res* 2011;26:229–38.
13. Schaffler MB, Cheung WY, Majeska R, *et al*. Osteocytes: master orchestrators of bone. *Calcif Tissue Int* 2014;94:5–24.
14. Xiong J, Onal M, Jilka RL, *et al*. Matrix-embedded cells control osteoclast formation. *Nat Med* 2011;17:1235–41.
15. Nakashima T, Hayashi M, Fukunaga T, *et al*. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. *Nat Med* 2011;17:1231–4.
16. Tatsumi S, Ishii K, Amizuka N, *et al*. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. *Cell Metab* 2007;5:464–75.
17. Kramer I, Halleux C, Keller H, *et al*. Osteocyte Wnt/ β -catenin signaling is required for normal bone homeostasis. *Mol Cell Biol* 2010;30:3071–85.
18. Cheng B, Kato Y, Zhao S, *et al*. PGE(2) is essential for gap junction-mediated intercellular communication between osteocyte-like MLO-Y4 cells in response to mechanical strain. *Endocrinology* 2001;142:3464–73.
19. Caballero-Alias AM, Loveridge N, Pitsillides A, *et al*. Osteocytic expression of constitutive NO synthase isoforms in the femoral neck cortex: a case–control study of intracapsular hip fracture. *J Bone Miner Res* 2005;20:268–73.
20. Sheng MH, Lau KH, Baylink DJ. Role of osteocyte-derived insulin-like growth factor I in developmental growth, modeling, remodeling, and regeneration of the bone. *J Bone Metab* 2014;21:41–54.
21. Kennedy OD, Laudier DM, Majeska RJ, *et al*. Osteocyte apoptosis is required for production of osteoclastogenic signals following bone fatigue in vivo. *Bone* 2014;64:132–7.
22. Lau KH, Baylink DJ, Zhou XD, *et al*. Osteocyte-derived insulin-like growth factor I is essential for determining bone mechanosensitivity. *Am J Physiol Endocrinol Metab* 2013;305:E271–81.
23. Yin J, Hao Z, Ma Y, *et al*. Concomitant activation of the PI3K/Akt and ERK1/2 signalling is involved in cyclic compressive force-induced IL-6 secretion in MLO-Y4 cells. *Cell Biol Int* 2014;38:591–8.

24. Heino J, Hentunen TA, Vaananen HK. Osteocytes inhibit osteoclastic bone resorption through transforming factor-beta; enhancement by estrogen. *J Cell Biochem* 2002;85:185–97.
25. Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. *Nat Rev Endocrinol* 2012;8:276–86.
26. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Med* 2013;19:179–92.
27. Robling AG, Bellido T, Turner CH. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. *J Musculoskelet Neuronal Interact* 2006;6:354.
28. Robling AG, Niziolek PJ, Baldridge LA, *et al.* Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. *J Biol Chem* 2008;283:5866–75.
29. Tu X, Rhee Y, Condon KW, *et al.* Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. *Bone* 2012;50:209–17.
30. Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. *Bone* 2013;54:250–7.
31. Keller H, Kneissel M. SOST is a target gene for PTH in bone. *Bone* 2005;37:148–58.
32. Rhee Y, Allen MR, Condon K, *et al.* PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. *J Bone Miner Res* 2011;26:1035–46.
33. Ben-Awad AN, Delgado-Calle J, Tu X, *et al.* Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. *Endocrinology* 2014;155:2797–809.
34. Morse A, McDonald M, Kelly N, *et al.* Mechanical load increases in bone formation via a sclerostin-independent pathway. *J Bone Miner Res* 2014;29:2456–67.
35. Kennedy OD, Herman BC, Laudier DM, *et al.* Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. *Bone* 2012;50:1115–22.
36. Schaffler MB, Kennedy OD. Osteocyte signaling in bone. *Curr Osteoporos Rep* 2012;10:118–25.
37. Appel H, Maier R, Loddenkemper C, *et al.* Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. *J Rheumatol* 2010;37:823–8.
38. Chan BY, Fuller ES, Russell AK, *et al.* Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. *Osteoarthritis Cartilage* 2011;19:874–85.
39. Funck-Brentano T, Bouaziz W, Marty C, *et al.* Dkk1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis. *Arthritis Rheumatol* 2014;66:3028–39.
40. Roudier M, Li X, Niu QT, *et al.* Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. *Arthritis and Rheum* 2013;65:721–31.